661 related articles for article (PubMed ID: 27140204)
1. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
Ambrosy AP; Khan H; Udelson JE; Mentz RJ; Chioncel O; Greene SJ; Vaduganathan M; Subacuis HP; Konstam MA; Swedberg K; Zannad F; Maggioni AP; Gheorghiade M; Butler J
Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27140204
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
[TBL] [Abstract][Full Text] [Related]
3. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438
[TBL] [Abstract][Full Text] [Related]
4. Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial).
Cook TD; Greene SJ; Kalogeropoulos AP; Fonarow GC; Zea R; Swedberg K; Zannad F; Maggioni AP; Konstam MA; Gheorghiade M; Butler J
Am J Cardiol; 2016 Feb; 117(4):611-616. PubMed ID: 26742474
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
Greene SJ; Vaduganathan M; Wilcox JE; Harinstein ME; Maggioni AP; Subacius H; Zannad F; Konstam MA; Chioncel O; Yancy CW; Swedberg K; Butler J; Bonow RO; Gheorghiade M;
JACC Heart Fail; 2013 Dec; 1(6):488-96. PubMed ID: 24622000
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
Gheorghiade M; Orlandi C; Burnett JC; Demets D; Grinfeld L; Maggioni A; Swedberg K; Udelson JE; Zannad F; Zimmer C; Konstam MA
J Card Fail; 2005 May; 11(4):260-9. PubMed ID: 15880334
[TBL] [Abstract][Full Text] [Related]
7. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
[TBL] [Abstract][Full Text] [Related]
8. Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure.
Vaduganathan M; Marti CN; Mentz RJ; Greene SJ; Ambrosy AP; Subacius HP; Fonarow GC; Chioncel O; Bazari H; Maggioni AP; Zannad F; Konstam MA; Sato N; Gheorghiade M; Butler J;
Am J Cardiol; 2016 Apr; 117(7):1144-50. PubMed ID: 26851146
[TBL] [Abstract][Full Text] [Related]
9. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial.
Mentz RJ; Greene SJ; Ambrosy AP; Vaduganathan M; Subacius HP; Swedberg K; Maggioni AP; Nodari S; Ponikowski P; Anker SD; Butler J; Gheorghiade M
Circ Heart Fail; 2014 May; 7(3):401-8. PubMed ID: 24737459
[TBL] [Abstract][Full Text] [Related]
10. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).
Lala A; McNulty SE; Mentz RJ; Dunlay SM; Vader JM; AbouEzzeddine OF; DeVore AD; Khazanie P; Redfield MM; Goldsmith SR; Bart BA; Anstrom KJ; Felker GM; Hernandez AF; Stevenson LW
Circ Heart Fail; 2015 Jul; 8(4):741-8. PubMed ID: 26041600
[TBL] [Abstract][Full Text] [Related]
11. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.
Kociol RD; McNulty SE; Hernandez AF; Lee KL; Redfield MM; Tracy RP; Braunwald E; O'Connor CM; Felker GM;
Circ Heart Fail; 2013 Mar; 6(2):240-5. PubMed ID: 23250981
[TBL] [Abstract][Full Text] [Related]
12. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
Mecklai A; Subačius H; Konstam MA; Gheorghiade M; Butler J; Ambrosy AP; Katz SD
JACC Heart Fail; 2016 Jul; 4(7):580-588. PubMed ID: 27039131
[TBL] [Abstract][Full Text] [Related]
13. Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial.
Dunlay SM; Gheorghiade M; Reid KJ; Allen LA; Chan PS; Hauptman PJ; Zannad F; Maggioni AP; Swedberg K; Konstam MA; Spertus JA
Eur J Heart Fail; 2010 Apr; 12(4):367-74. PubMed ID: 20197265
[TBL] [Abstract][Full Text] [Related]
14. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
[TBL] [Abstract][Full Text] [Related]
15. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).
Khan SS; Campia U; Chioncel O; Zannad F; Rossignol P; Maggioni AP; Swedberg K; Konstam MA; Senni M; Nodari S; Vaduganathan M; Subacius H; Butler J; Gheorghiade M;
Am J Cardiol; 2015 Mar; 115(6):790-6. PubMed ID: 25728846
[TBL] [Abstract][Full Text] [Related]
16. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Lanfear DE; Sabbah HN; Goldsmith SR; Greene SJ; Ambrosy AP; Fought AJ; Kwasny MJ; Swedberg K; Yancy CW; Konstam MA; Maggioni AP; Zannad F; Gheorghiade M;
Circ Heart Fail; 2013 Jan; 6(1):47-52. PubMed ID: 23239836
[TBL] [Abstract][Full Text] [Related]
17. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
O'Connor CM; Miller AB; Blair JE; Konstam MA; Wedge P; Bahit MC; Carson P; Haass M; Hauptman PJ; Metra M; Oren RM; Patten R; Piña I; Roth S; Sackner-Bernstein JD; Traver B; Cook T; Gheorghiade M;
Am Heart J; 2010 May; 159(5):841-849.e1. PubMed ID: 20435194
[TBL] [Abstract][Full Text] [Related]
18. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Greene SJ; Gheorghiade M; Vaduganathan M; Ambrosy AP; Mentz RJ; Subacius H; Maggioni AP; Nodari S; Konstam MA; Butler J; Filippatos G;
Eur J Heart Fail; 2013 Dec; 15(12):1401-11. PubMed ID: 23845795
[TBL] [Abstract][Full Text] [Related]
19. Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial.
Abualnaja S; Podder M; Hernandez AF; McMurray JJ; Starling RC; O'Connor CM; Califf RM; Armstrong PW; Ezekowitz JA
J Am Heart Assoc; 2015 Aug; 4(8):e002092. PubMed ID: 26304935
[TBL] [Abstract][Full Text] [Related]
20. Home-Delivered Meals Postdischarge From Heart Failure Hospitalization.
Hummel SL; Karmally W; Gillespie BW; Helmke S; Teruya S; Wells J; Trumble E; Jimenez O; Marolt C; Wessler JD; Cornellier ML; Maurer MS
Circ Heart Fail; 2018 Aug; 11(8):e004886. PubMed ID: 30354562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
